Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Research

The association between jaundice and poorly differentiated pancreatic neuroendocrine neoplasms (Ki67 index > 55.0%)

Authors: Yongkang Liu, Jiangchuan Wang, Hao Zhou, Zicheng Wei, Jianhua Wang, Zhongqiu Wang, Xiao Chen

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Jaundice occurs in some pancreatic disease. However, its occurrences and role in pancreatic neuroendocrine neoplasms (PNENs) has not been well studied. In this study we showed the association between jaundice and the risk of high grade and poorly differentiated PNENs.

Methods

Ninety-three patients with head-neck PNENs were included. Poorly differentiated pancreatic neuroendocrine neoplasms were defined by a ki67 index > 55.0%. Logistic regression was used to show the association between demographic information, clinical signs and symptoms and the risk of poorly differentiated tumors. A nomogram model was developed to predict poorly differentiated tumor.

Results

Eight of 93 PNEN patients (8.6%) had jaundice. The age and ki67 index in patients with jaundice were significantly higher than those patients without jaundice. All jaundice occurred in patients with grade 3 PNENs. Mutivariable regression analysis showed that age (odds ratio(OR) = 1.10, 95% confidence interval (CI):1.02–1.19), tumor size (OR = 1.42, 95%CI:1.01-2.00) and jaundice (OR = 14.98, 95%CI: 1.22-184.09) were associated with the risk of poorly differentiated PNENs. The age and size combination showed a good performance in predicting poorly differentiated PNENs (area under the curve (AUC) = 0.81, 95% CI: 0.71–0.90). The addition of jaundice further improved the age- and size-based model (AUC = 0.86, 95% CI: 0.78–0.91). A nomogram was developed based on age, tumor size and jaundice.

Conclusion

Our data showed that jaundice was associated with the risk of high grade PNENs and poorly differentiated PNENs.
Literature
1.
go back to reference Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18.CrossRefPubMed Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18.CrossRefPubMed
2.
go back to reference Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. Determining prognosis in patients with pancreatic endocrine Neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25(35):5609–15.CrossRefPubMed Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. Determining prognosis in patients with pancreatic endocrine Neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25(35):5609–15.CrossRefPubMed
3.
go back to reference Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O’Dorisio TM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(7):863–81.CrossRefPubMed Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O’Dorisio TM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(7):863–81.CrossRefPubMed
4.
go back to reference Bian Y, Jiang H, Ma C, Wang L, Zheng J, Jin G, et al. CT-Based Radiomics score for distinguishing between Grade 1 and Grade 2 nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2020;215(4):852–63.CrossRefPubMed Bian Y, Jiang H, Ma C, Wang L, Zheng J, Jin G, et al. CT-Based Radiomics score for distinguishing between Grade 1 and Grade 2 nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2020;215(4):852–63.CrossRefPubMed
5.
go back to reference Canellas R, Burk KS, Parakh A, Sahani DV. Prediction of pancreatic neuroendocrine Tumor Grade based on CT Features and texture analysis. AJR Am J Roentgenol. 2018;210(2):341–6.CrossRefPubMed Canellas R, Burk KS, Parakh A, Sahani DV. Prediction of pancreatic neuroendocrine Tumor Grade based on CT Features and texture analysis. AJR Am J Roentgenol. 2018;210(2):341–6.CrossRefPubMed
6.
go back to reference Chen HY, Zhang XY, Deng XY, Ge YL, Tang YQ, Cui H, et al. Grade 3 pancreatic neuroendocrine tumors on MDCT: establishing a diagnostic model and comparing survival against pancreatic ductal adenocarcinoma. AJR Am J Roentgenol. 2020;215(2):390–7.CrossRefPubMed Chen HY, Zhang XY, Deng XY, Ge YL, Tang YQ, Cui H, et al. Grade 3 pancreatic neuroendocrine tumors on MDCT: establishing a diagnostic model and comparing survival against pancreatic ductal adenocarcinoma. AJR Am J Roentgenol. 2020;215(2):390–7.CrossRefPubMed
7.
go back to reference Choi TW, Kim JH, Yu MH, Park SJ, Han JK. Pancreatic neuroendocrine Tumor: prediction of the Tumor grade using CT findings and computerized texture analysis. Acta Radiol. 2018;59(4):383–92.CrossRefPubMed Choi TW, Kim JH, Yu MH, Park SJ, Han JK. Pancreatic neuroendocrine Tumor: prediction of the Tumor grade using CT findings and computerized texture analysis. Acta Radiol. 2018;59(4):383–92.CrossRefPubMed
8.
go back to reference Oh D, Pyo JS, Chung KH, Son BK. The Predicting role of the neutrophil-to-lymphocyte ratio for the Tumor Gradeand Prognosis in pancreatic neuroendocrine tumors. Diagnostics (Basel). 2022;12(3):737.CrossRefPubMed Oh D, Pyo JS, Chung KH, Son BK. The Predicting role of the neutrophil-to-lymphocyte ratio for the Tumor Gradeand Prognosis in pancreatic neuroendocrine tumors. Diagnostics (Basel). 2022;12(3):737.CrossRefPubMed
9.
go back to reference Kim H, An S, Lee K, Ahn S, Park DY, Kim JH, et al. Pancreatic high-Grade Neuroendocrine Neoplasms in the Korean Population: a Multicenter Study. Cancer Res Treat. 2020;52(1):263–76.CrossRefPubMed Kim H, An S, Lee K, Ahn S, Park DY, Kim JH, et al. Pancreatic high-Grade Neuroendocrine Neoplasms in the Korean Population: a Multicenter Study. Cancer Res Treat. 2020;52(1):263–76.CrossRefPubMed
11.
go back to reference Liao W, Clift AK, Patone M, Coupland C, González-Izquierdo A, Pereira SP, et al. Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine Neoplasms: a nested case-control study of the UK primary care population. Br J Gen Pract. 2021;71(712):e836–45.CrossRefPubMedPubMedCentral Liao W, Clift AK, Patone M, Coupland C, González-Izquierdo A, Pereira SP, et al. Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine Neoplasms: a nested case-control study of the UK primary care population. Br J Gen Pract. 2021;71(712):e836–45.CrossRefPubMedPubMedCentral
12.
go back to reference Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in Primary Care: A Systematic Review Pancreas. 2016;45(6):814–8.PubMed Schmidt-Hansen M, Berendse S, Hamilton W. Symptoms of Pancreatic Cancer in Primary Care: A Systematic Review Pancreas. 2016;45(6):814–8.PubMed
13.
go back to reference Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.CrossRefPubMed Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.CrossRefPubMed
14.
go back to reference Kloppel G, Couvelard A, Hruban RH, et al. Neoplasms of the neuroendocrine pancreas. Introduction. In: Kloppel G, Osamura RY, Lloyd RV, et al. editors. WHO classification of tumours of the endocrine organs. Lyon (France): IARC; 2017. pp. 211–4. Kloppel G, Couvelard A, Hruban RH, et al. Neoplasms of the neuroendocrine pancreas. Introduction. In: Kloppel G, Osamura RY, Lloyd RV, et al. editors. WHO classification of tumours of the endocrine organs. Lyon (France): IARC; 2017. pp. 211–4.
15.
go back to reference European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic Neoplasms. Gut. 2018;67(5):789–804.CrossRef European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic Neoplasms. Gut. 2018;67(5):789–804.CrossRef
16.
go back to reference Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.CrossRefPubMed Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.CrossRefPubMed
17.
go back to reference Massironi S, Rossi RE, Laffusa A, Eller-Vainicher C, Cavalcoli F, Zilli A, et al. Sporadic and MEN1-related gastrinoma and zollinger-Ellison syndrome: differences in clinical characteristics and survival outcomes. J Endocrinol Invest. 2023;46(5):957–65.CrossRefPubMed Massironi S, Rossi RE, Laffusa A, Eller-Vainicher C, Cavalcoli F, Zilli A, et al. Sporadic and MEN1-related gastrinoma and zollinger-Ellison syndrome: differences in clinical characteristics and survival outcomes. J Endocrinol Invest. 2023;46(5):957–65.CrossRefPubMed
18.
go back to reference Sonoda A, Yamashita YI, Kondo T, Hayashi H, Imai K, Higashi T, et al. Clinicopathological features and menin expression of pancreatic neuroendocrine Neoplasm associated with multiple endocrine neoplasia type 1. J Hepatobiliary Pancreat Sci. 2020;27(12):984–91.CrossRefPubMedPubMedCentral Sonoda A, Yamashita YI, Kondo T, Hayashi H, Imai K, Higashi T, et al. Clinicopathological features and menin expression of pancreatic neuroendocrine Neoplasm associated with multiple endocrine neoplasia type 1. J Hepatobiliary Pancreat Sci. 2020;27(12):984–91.CrossRefPubMedPubMedCentral
19.
go back to reference Busico A, Maisonneuve P, Prinzi N, Pusceddu S, Centonze G, Garzone G, et al. Gastroenteropancreatic high-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, two sides of the same Coin. Neuroendocrinology. 2020;110(7–8):616–29.CrossRefPubMed Busico A, Maisonneuve P, Prinzi N, Pusceddu S, Centonze G, Garzone G, et al. Gastroenteropancreatic high-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, two sides of the same Coin. Neuroendocrinology. 2020;110(7–8):616–29.CrossRefPubMed
20.
go back to reference Fang JM, Shi J. A clinicopathologic and molecular update of pancreatic neuroendocrine Neoplasms with a focus on the New World Health Organization classification. Arch Pathol Lab Med. 2019;143(11):1317–26.CrossRefPubMedPubMedCentral Fang JM, Shi J. A clinicopathologic and molecular update of pancreatic neuroendocrine Neoplasms with a focus on the New World Health Organization classification. Arch Pathol Lab Med. 2019;143(11):1317–26.CrossRefPubMedPubMedCentral
21.
go back to reference Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.Histopathology. 2018;72(1):168–177. Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.Histopathology. 2018;72(1):168–177.
22.
go back to reference Massironi S, Cavalcoli F, Artoni A, Sciola V, Zilli A, Ciafardini C, et al. Thrombotic risk in gastroenteropancreatic neuroendocrine Tumor patients: a single-center experience. Ann Gastroenterol. 2021;34(4):588–93.PubMedPubMedCentral Massironi S, Cavalcoli F, Artoni A, Sciola V, Zilli A, Ciafardini C, et al. Thrombotic risk in gastroenteropancreatic neuroendocrine Tumor patients: a single-center experience. Ann Gastroenterol. 2021;34(4):588–93.PubMedPubMedCentral
23.
go back to reference Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, et al. Chromogranin A in diagnosing and monitoring patients with ggastroenteropancreatic neuroendocrine Neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2–3):240–9.CrossRefPubMed Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, et al. Chromogranin A in diagnosing and monitoring patients with ggastroenteropancreatic neuroendocrine Neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2–3):240–9.CrossRefPubMed
24.
go back to reference Korse CM, Taal BG, Vincent A, van Velthuysen ML, Baas P, Buning-Kager JC, et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, Neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer. 2012;48(5):662–71.CrossRefPubMed Korse CM, Taal BG, Vincent A, van Velthuysen ML, Baas P, Buning-Kager JC, et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, Neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer. 2012;48(5):662–71.CrossRefPubMed
25.
go back to reference Zouli C, Zisimopoulou E, Chrisoulidou ABiomarkers in neuroendocrine neoplasms. Hell J Nucl Med. 2023; 26 Suppl:44–48. Zouli C, Zisimopoulou E, Chrisoulidou ABiomarkers in neuroendocrine neoplasms. Hell J Nucl Med. 2023; 26 Suppl:44–48.
26.
go back to reference Centonze G, Maisonneuve P, Prinzi N, Pusceddu S, Albarello L, Pisa E, et al. Prognostic factors across poorly differentiated neuroendocrine Neoplasms: a pooled analysis. Neuroendocrinology. 2023;113(4):457–69.CrossRefPubMed Centonze G, Maisonneuve P, Prinzi N, Pusceddu S, Albarello L, Pisa E, et al. Prognostic factors across poorly differentiated neuroendocrine Neoplasms: a pooled analysis. Neuroendocrinology. 2023;113(4):457–69.CrossRefPubMed
27.
go back to reference Milione M, Maisonneuve P, Grillo F, Mangogna A, Centonze G, Prinzi N, et al. Ki-67 index of 55% distinguishes two groups of bronchopulmonary pure and Composite large cell neuroendocrine carcinomas with distinct prognosis. Neuroendocrinology. 2021;111(5):475–89.CrossRefPubMed Milione M, Maisonneuve P, Grillo F, Mangogna A, Centonze G, Prinzi N, et al. Ki-67 index of 55% distinguishes two groups of bronchopulmonary pure and Composite large cell neuroendocrine carcinomas with distinct prognosis. Neuroendocrinology. 2021;111(5):475–89.CrossRefPubMed
28.
go back to reference Shi H, Chen L, Zhang Q, Lin Y, Jiang C, Yao H, et al. Concordance between the Ki-67 Index Cutoff Value of 55% and differentiation in neuroendocrine Tumor and neuroendocrine carcinoma in Grade 3 pancreatic neuroendocrine Neoplasms. Pancreas. 2020;49(10):1378–82.CrossRefPubMed Shi H, Chen L, Zhang Q, Lin Y, Jiang C, Yao H, et al. Concordance between the Ki-67 Index Cutoff Value of 55% and differentiation in neuroendocrine Tumor and neuroendocrine carcinoma in Grade 3 pancreatic neuroendocrine Neoplasms. Pancreas. 2020;49(10):1378–82.CrossRefPubMed
Metadata
Title
The association between jaundice and poorly differentiated pancreatic neuroendocrine neoplasms (Ki67 index > 55.0%)
Authors
Yongkang Liu
Jiangchuan Wang
Hao Zhou
Zicheng Wei
Jianhua Wang
Zhongqiu Wang
Xiao Chen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-03076-9

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.